February 13, 2013 at 07:33 AM EST
Protalix Says New Clinical Data on ELELYSO Will Be Presented at WORLD Symposium
Protalix BioTherapeutics, Inc. (NYSE: PLX ), announced today that new clinical data on ELELYSO™ (taliglucerase alfa) will be presented at the 9th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2013 being held February 13-15 in Orlando, Florida. ELELYSO, the Company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here